Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Hologic (NASDAQ:HOLX) on Wednesday, setting a price target of $62, which is approximately 18.18% below the present share price of $75.78.
Matson expects Hologic to post earnings per share (EPS) of $1.90 for the first quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Hologic, with an average price target of $90.5.
The analysts price targets range from a high of $106 to a low of $81.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.35 billion and a net profit of $643.3 million. The company's market cap is $19.53 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.2% and a 68.22% success rate.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.